B. Riley Wealth Management’s Allogene Therapeutics ALLO Stock Holding History

B. Riley Wealth Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2.69K	Buy	+636	New	+$5.65K	﹤0.01%	185

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

B. Riley Wealth Management's ALLO Position: Q2 2022 in Review

B. Riley Wealth Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2022: 636 shares worth $2.69K. The stake represents ﹤0.01% of the portfolio and ranks #185 among its holdings.

161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

B. Riley Wealth Management held 636 shares of Allogene Therapeutics worth $2.69K as of Q2 2022.
Allogene Therapeutics was a new B. Riley Wealth Management position in Q2 2022.
Allogene Therapeutics made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #185 holding.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.